Seth Lederman, Chief Executive Officer at Tonix Pharmaceuticals Holding Corp. (TNXP), bought 5,000 shares at $12.62 ($63K) on 2026-03-31, disclosed to the SEC on 2026-04-01.
CEO Seth Lederman purchased 5,000 shares of Tonix Pharmaceuticals for $63,100, signaling confidence in the company's commercial traction. This executive buy comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
TNXP is down 8.8% over the last 5 days and 21.6% over the past year, trading at $13.68, which is 17.93% above its 52-week low of $11.60.
1) Q2 2026 Earnings Call on 2026-08-10: The company reported record TONMYA sales of $11 million with prescriptions doubling quarter-over-quarter. 2) Medicare Expansion: A new payer agreement on 2026-07-13 extends TONMYA coverage to an additional 9 million Medicare beneficiaries. 3) TNX-801 Vaccine Data: Encouraging preclinical data for the mpox and smallpox vaccine candidate was presented at the World Vaccine Congress Europe on 2025-10-29.
1) High Short Interest: The stock has a short interest of 21.47% of the float, indicating significant bearish sentiment. 2) Recent Dilution: The company priced a registered direct offering of 615,025 shares at $16.26 on 2025-12-30, which could dilute existing shareholders.
Something here stands out, but not much.
| Filing → |
| TNXP | BUY | 2026-03-18 | $223K | — | Filing → |
| TNXP | BUY | 2025-05-15 | $86K | — | Filing → |
| TNXP | BUY | 2022-07-01 | $34K | — | Filing → |